KYORIN Sets Aggressive Investment Plan in New Medium-Term Strategy “Vision 110 – Stage 2 –”

KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) just unveiled an announcement.

KYORIN Pharmaceutical has unveiled its new medium-term business plan, “Vision 110 – Stage 2 –,” covering fiscal years 2026 to 2029 as part of a broader long-term strategy leading up to its 110th anniversary. The plan centers on “Aggressive Investment for Sustainable Growth,” prioritizing the acquisition of in-licensed products and other assets, expansion of the development pipeline, maximization of new drug market penetration, and reinforcement of healthcare-related businesses with synergies to its pharmaceuticals segment.

As key performance targets, KYORIN is aiming for at least ¥120 billion in net sales and operating profit before R&D of ¥17 billion or more by fiscal 2029, with a return on equity of at least 5%, compared with fiscal 2025 results. The company will prioritize investment to strengthen its pipeline beyond Stage 3 while maintaining an annual dividend of ¥25 per share and considering potential dividend increases depending on business performance and cash flow, signaling a balance between growth investment and shareholder returns.

More about KYORIN Pharmaceutical Co.,Ltd.

KYORIN Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the TSE Prime that focuses on the development, in-licensing, and commercialization of prescription drugs. The company aims to strengthen its drug discovery capabilities and expand its pipeline to deliver high-value new medicines while also promoting healthcare-related businesses that complement its core pharmaceuticals operations.

Average Trading Volume: 104,171

Technical Sentiment Signal: Buy

Current Market Cap: Yen81.59B

For a thorough assessment of 4569 stock, go to TipRanks’ Stock Analysis page.